Expert perspectives on cholangiocarcinoma (CCA)

Molecular profiling: Challenges and opportunities in cholangiocarcinoma (ILCA 2022)

Dr Teresa Macarulla

Vall d’Hebron University Hospital,
Barcelona, Spain

Advances in molecular profiling techniques for cholangiocarcinoma (ECP 2022)

Dr Daniel Kazdal

Centre for Molecular Pathology,
University Hospital Heidelberg,
Heidelberg, Germany

Biopsy collection in cholangiocarcinoma: Current status and future perspectives (ECP 2022)

Dr Ana Vivancos

Vall d’Hebron Institute of Oncology,
Barcelona, Spain

Optimising molecular profiling and the multidisciplinary team approach in cholangiocarcinoma (ESMO 2022)

Dr Angela Lamarca

Fundación Jiménez Díaz University Hospital, Spain

Optimising molecular profiling in CCA (ESMO GI 2022)

Professor John Bridgewater

Clinical Professor, University College London Cancer Institute, London, UK

Detecting FGFR2 fusions in patients with CCA (ESMO GI 2021)

Dr Nicola Normanno

Istituto Nazionale per lo Studio e la Cura dei Tumori. Fondazione G. Pascale, Italy

Perspectives on precision medicine in CCA (2021)

Listen to Professor Eric Van Cutsem and Dr Angela Lamarca provide expert perspectives on key questions in precision medicine and molecular testing in advanced CCA

Professor Eric Van Cutsem

University Hospitals Gasthuisberg Leuven and
KU Leuven, Belgium

Dr Angela Lamarca

Fundación Jiménez Díaz University Hospital, Spain

Importance of biomarkers in CCA (ESMO GI 2021)

Dr Angela Lamarca

Fundación Jiménez Díaz University Hospital, Spain

Importance of molecular profiling in patients with CCA (ESMO 2020)

Professor Lorenza Rimassa

Associate Professor of Medical Oncology, Humanitas University and IRCCS Humanitas Research Hospital, Milan, Italy

Helen Morement

CEO and Founder of AMMF - The Cholangiocarcinoma Charity, London, UK

Professor Juan Valle

University of Manchester & The Christie, Manchester, UK

Professor Peter Schirmacher

Institute of Pathology, University Hospital Heidelberg

All videos in this category

Molecular profiling: Challenges and opportunities in cholangiocarcinoma Thumbnail

Molecular profiling: Challenges and opportunities in cholangiocarcinoma (ILCA 2022)

Advances in molecular profiling techniques for cholangiocarcinoma Thumbnail

Advances in molecular profiling techniques for cholangiocarcinoma (ECP 2022)

Biopsy collection in cholangiocarcinoma: Current status and future perspectives Thumbnail

Biopsy collection in cholangiocarcinoma: Current status and future perspectives (ECP 2022)

Optimising molecular profiling and the multidisciplinary team approach in cholangiocarcinoma Thumbnail

Optimising molecular profiling and the multidisciplinary team approach in cholangiocarcinoma (ESMO 2022)

Optimising molecular profiling in CCA Thumbnail

Optimising molecular profiling in CCA (ESMO GI 2022)

Detecting FGFR2 fusions in patients with CCA Thumbnail

Detecting FGFR2 fusions in patients with CCA (ESMO GI 2021)

Perspectives on precision medicine in CCA (2021)

Importance of biomarkers in CCA Thumbnail

Importance of biomarkers in CCA (ESMO GI 2021)

Importance of molecular profiling in patients with CCA Thumbnail

Importance of molecular profiling in patients with CCA (ESMO 2020)

Company/Organisation	Relationship(s)
Ability Pharmaceuticals SL, Aptitude Health, AstraZeneca, Basilea Pharma, Baxter, BioLineRX Ltd, Celgene, Eisai, Ellipses, Genzyme, Got It Consulting SL, Hirslanden/GITZ, Imedex, Incyte, Ipsen Bioscience Inc, Janssen, Lilly, Marketing Farmacéutico & Investigación Clínica S.L, MDS, Medscape, Novocure, Paraxel, Polaris, PPD Development, QED Therapeutics, Roche Farma, Sanofi-Aventis, Scilink Comunicación Científica SC, Servier, Surface Oncology, Swedish Orphan Biovitrum AB, Zymeworks	Advisory role Speaker’s fee Direct research fund
AbbVie Farmaceútica, Ability Pharmaceuticals, Agios Pharmaceuticals, Amc Medical Research, Amgen, Armo Biosciences, Aslan Pharmaceuticals, Astrazeneca, Basilea Pharmaceutica International, Bayer, Beigene, Biokeralty Research Institute, Biolinerx, Blueprint Medicines, Boston Biomedical, Bristol-Myers Squibb (BMS), Cantargia, Celgene, Eisai, Erytech Pharma, F. Hoffmann-la Roche, Fibrogen, Halozyme, Incyte, Ipsen Bioscience, Ipsen Pharma, Lilly, Loxo Oncology, Medimmune, Merck Sharp & Dohme, Nelum, Novartis, Novocure, Oncomed Pharmaceuticals, QED Therapeutics, VCN Biosciences, Zymeworks	Clinical trial support

Company/Organisation	Relationship(s)
Personal funding	Agilent, AstraZeneca, Bristol Myers Squibb, Incyte, Lilly, Pfizer, Takeda

Company/Organisation	Relationship(s)
Bayer, BMS, Guardant Health, Incyte, Merck, Novartis, Roche	Advisory board

Company/Organisation	Relationship(s)
Albireo Pharma, AstraZeneca, Boehringer Ingelheim, Boston Scientific, Eisai, GenFit, Nutricia Ipsen, QED, Roche, Servier and TransThera Biosciences	Receipt of honoraria or consultation fees
AAA, AstraZeneca, Eisai, Incyte, Ipsen, Merck, Pfizer, QED, Roche and Servier	Participation in company-sponsored speaker bureau
AAA, Bayer, Delcath, Ipsen, Mylan, Novartis, Pfizer and Sirtex	Travel, education funding
Ipsen and Roche	Research funding

Company/Organisation	Relationship(s)
Amgen, AstraZeneca, Basilea, Bayer, Bristol-Myers Squibb, Celgene, Incyte, Medarex, Merck Serono, MSD Oncology, Roche, Servier	Support

Disclosures

Dr Nicola Normanno:

Company/Organisation	Relationship(s)
MSD, Qiagen, Bayer, Biocartis, Illumina, Incyte, Roche, BMS, Merck, Thermo Fisher, Boehringer Ingelheim, AstraZeneca, Sanofi, Eli Lilly	Personal financial interests (speaker’s fee and/or advisory boards)
Merck, Sysmex, Thermo Fisher, QIAGEN, Roche, AstraZeneca, Biocartis, Illumina	Institutional financial interests (financial support to research projects)
President, International Quality Network for Pathology (IQN Path); President, Italian Cancer Society (SIC)	Non-financial interests

Company/Organisation	Relationship(s)
Incyte	Consultant
Amgen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Ipsen, Lilly, Merck Sharp & Dohme, Merck KGaA, Novartis, Roche, Servier	Research grants
Array, Astellas, AstraZeneca, Bayer, Beigene, Biocartis, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Daiichi, Halozyme, GSK, Incyte, Ipsen, Lilly, Merck Sharp & Dohme, Merck KGaA, Novartis, Pierre Fabre, Roche, Servier, Sirtex Medical, Taiho	Advisory boards

Company/Organisation	Relationship(s)
Amgen, ArQule, AstraZeneca, Basilea, Bayer, BMS, Celgene, Eisai, Exelixis, Genenta, Hengrui, Incyte, Ipsen, IQVIA, Lilly, MSD, Nerviano Medical Sciences, Roche, Sanofi, Servier, Taiho Oncology, Zymeworks	Consulting/Advisory role
AbbVie, Amgen, Bayer, Eisai, Gilead, Incyte, Ipsen, Lilly, Merck Serono, Roche, Sanofi, Servier	Honoraria/Lectures
AstraZeneca	Travel expenses
Agios, ARMO BioSciences, AstraZeneca, BeiGene, Eisai, Exelixis, Fibrogen, Incyte, Ipsen, Lilly, MSD, Nerviano Medical Sciences, Roche, Zymeworks	Research funding to institution

Company/Organisation	Relationship(s)
Imaging Equipment Ltd, Ipsen, Novartis, NuCana	Speakers bureau
Celgene, NuCana	Travel grant
Agios, AstraZeneca, Debiopharm, Delcath Systems, GenoScience Pharma, Imaging Equipment Ltd, Incyte, Ipsen, Keocyt, Merck, Mundipharma EDO, Novartis, NuCana, PCI Biotech, Pieris Pharmaceuticals, Pfizer, QED, Servier, Wren Laboratories	Grant support

Company/Organisation	Relationship(s)
AstraZeneca, Incyte, Janssen, Novartis, Roche	Speakers bureau
Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Incyte, Janssen, Merck Sharp & Dohme, Novartis, Roche	Board
AstraZeneca, Bristol Myers Squibb, Illumina, Novartis	Grant support

Expert perspectives on cholangiocarcinoma (CCA)

Molecular profiling: Challenges and opportunities in cholangiocarcinoma (ILCA 2022)

Advances in molecular profiling techniques for cholangiocarcinoma (ECP 2022)

Biopsy collection in cholangiocarcinoma: Current status and future perspectives (ECP 2022)

Optimising molecular profiling and the multidisciplinary team approach in cholangiocarcinoma (ESMO 2022)

Optimising molecular profiling in CCA (ESMO GI 2022)

Detecting FGFR2 fusions in patients with CCA (ESMO GI 2021)

Perspectives on precision medicine in CCA (2021)

Importance of biomarkers in CCA (ESMO GI 2021)

Importance of molecular profiling in patients with CCA (ESMO 2020)

All videos in this category

Molecular profiling: Challenges and opportunities in cholangiocarcinoma (ILCA 2022)

Advances in molecular profiling techniques for cholangiocarcinoma (ECP 2022)

Biopsy collection in cholangiocarcinoma: Current status and future perspectives (ECP 2022)

Optimising molecular profiling and the multidisciplinary team approach in cholangiocarcinoma (ESMO 2022)

Optimising molecular profiling in CCA (ESMO GI 2022)

Detecting FGFR2 fusions in patients with CCA (ESMO GI 2021)

Perspectives on precision medicine in CCA (2021)

Importance of biomarkers in CCA (ESMO GI 2021)

Importance of molecular profiling in patients with CCA (ESMO 2020)

Enhance your CCA knowledge with Incyteful